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Abstract
Background: To determine infection rate with use of epidural catheters in place for seven days
or more.
Methods: Systematic review and pooled analysis of observational studies.
Results: Twelve studies with 4,628 patients (median 197 patients) provided information, of which
nine (4,334 patients) were published after 1990. Eight studies (3,893 patients) were retrospective,
and four studies (735 patients) prospective. Electronic searches identified three studies and
searching reference lists nine.
There were 257 catheter-related infections in total, of which 211 were superficial and 57 deep,
giving rates of 6.1%, 4.6% and 1.2% respectively. Ten of the 12 studies had deep infection rates of
2% or less. The incidence of deep infection was 1 per 2391 days of treatment, or 0.4 per 1000
catheter treatment days. In nine studies (1503 patients), predominantly in cancer, and with average
catheter duration of 74 days, the deep infection rate was 2.8%. The proportion of patients with
infection of any type was higher in cancer patients with longer catheter duration. Limited numbers
of events meant that no reliable estimate of the impact of prospective and retrospective design
could be made. There appeared to be a relationship between catheter duration and infection rate
from this and other recent estimates. Four of 57 (7%) patients with deep infection died.
Conclusion: The best estimate is that one person in 35 with an epidural catheter in place for 74
days for relief of cancer pain can be expected to have a deep epidural infection, and that about 1
in 500 may die of infection-related causes. This is a most uncertain estimate given the limited nature
of the evidence.
Background
Managing very severe pain is important and not always
easy. Not all patients receiving appropriate conventional
analgesics for nociceptive pain experience adequate pain
relief, and some suffer from intolerable adverse effects.
Changing delivery route from oral to epidural for opioids
is one strategy in this situation [1,2]. Epidural drug deliv-
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ery may also be used to manage severe neuropathic or
movement-related pain.
A potential risk of epidural catheters is infection, and
infection in the epidural space can be a very serious com-
plication [3]. The clinical decision to implant an epidural
catheter is influenced by the predicted benefit and the risk
of complications. At present we do not have robust esti-
mates for the risk of infection in this situation.
Rates associated with short-term use of catheters in obstet-
rics have been calculated [4]: epidural haematoma 1 in
168,000 women, deep epidural infection 1 in 145,000,
persistent neurological injury 1 in 240,000, and transient
neurological injury 1 in 6,700. In obstetrics, though, cath-
eters would often be in place for less than a day, while in
cancer patients they may be in place for months. The aim
of this meta-analysis was to determine the rates of infec-
tion for epidural catheters in place for seven days or
longer.
Methods
Papers reporting on adverse events associated with epi-
dural catheters were identified using three different
approaches. First we carried out electronic searches in
PubMed (from 1966), MEDLINE (from 1966) and
EMBASE (from 1980) to February 2005, with no language
restrictions. The searches combined controlled vocabulary
and free text terms for both the intervention (epidural
catheter) and the outcome (adverse effect). Details of the
terms used are in additional file 1. Secondly we hand
searched five anaesthesia journals (Anesthesiology,
Anesthesia and Analgesia, British Journal of Anaesthesia,
Anaesthesia, Acta Anaestheseiologica Scandinavica) from
mid 1999 to February 2005. Thirdly, reference lists of
reviews and retrieved studies were checked for additional
studies.
The titles and abstracts of all retrieved articles were read,
and those clearly not relevant were eliminated. Full copies
of all the remaining studies were obtained and read. Those
reporting numerical data for serious adverse events were
included in an initial list of studies. We then selected
those reporting on at least 50 patients, with median cath-
eter duration of at least seven days, and with numerical
data for superficial infections (skin around catheter inser-
tion), deep infections (in the epidural space), or total
infections (deep and superficial), using the infection crite-
ria used by the original authors.
Information about the type of study, patients, interven-
tion, and numbers experiencing individual adverse out-
comes was tabulated. QUOROM guidelines [5] were
followed where applicable. It was the intention, where
there was sufficient clinical homogeneity, to pool results
and to calculate infection rates for deep and superficial
infections separately. We planned to perform sensitivity
analyses for larger versus smaller studies, studies pub-
lished before or after 1990 to reflect possible changes in
practice, and for perioperative patients and cancer
patients separately. Information on infections would be
presented in two ways: the percentage of patients with
deep, superficial, or any catheter-related infection, and the
incidence of infection per 1000 catheter treatment days.
Results
Initially 1,270 papers were identified, 270 of which
referred to epidural harm. Seventeen appeared to relate to
epidural catheters in place for at least seven days. We
excluded five of these papers (Figure 1), three [6-8]
because they were of short duration, one [9] had no
denominator, and one [10] provided information on only
30 patients. Only three [2,11,12] of the 12 remaining
studies were identified by electronic searches, and nine
[1,13-20] were found from reference lists. One study [17]
with 110 patients included 30 with subarachnoid injec-
tions, but no deep infections; because the numbers of sub-
arachnoid injections were tiny compared with the total
number of patients in the review, we included it.
Nine studies examined mainly cancer patients (1,481 can-
cer, 11 AIDS, 11 non-cancer), two [19,20] examined post-
operative patients, though including some patients with
cancer, and one [12] examined only patients with chronic
non-cancer pain (Table 1).
The 12 papers involved 4,628 patients having an epidural
catheter for at least seven days (full details of studies in
additional file 2). The number of patients in each study
ranged from 50 to 1621, median 197. Nine studies with
4,334 patients were published after 1990, and three with
294 patients before 1990 (Table 1); two studies published
after 1990 [19,20] accounted for more than half of the
total patients (2,621 patients). Eight studies (3,214
patients, at least 99,000 catheter days of follow up) were
retrospective, two of which examined non-cancer patients
[12,19]; four studies were prospective (1,414 patients,
36,000 catheter days [1,14,15,20]), one of which [20]
examined non-cancer patients.
One study [12] did not indicate the mean catheter dura-
tion, and another [17] included 30 patients with sub-
arachnoid injections. In the remaining 10 studies with
4,014 patients, the mean catheter duration for each study
ranged from seven to 96 days, with an overall mean of 57
days. The total number of catheter days in each study
ranged from 4,200 to 32,354. The overall number of
patient days was more than 135,000; of these, 111,000
were obtained in cancer studies and of those, 36,000 wereBMC Palliative Care 2007, 6:3 http://www.biomedcentral.com/1472-684X/6/3
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in three prospective studies and 78,000 in five retrospec-
tive studies.
Infection rates
Fifty-seven deep infections were reported in 12 studies
with 4,628 patients (Table 1), giving a deep infection rate
of 1.2% (95% CI 0.91 to 1.6) (Table 2). There was consid-
erable variation between individual studies (Figure 2),
though 10 of the 12 studies had deep infection rates of 2%
or less. The incidence of deep infection was 1 per 2391
days of treatment, or 0.4 per 1000 catheter treatment days.
There were 211 superficial infections in nine studies with
a total of 4,235 patients (Table 1), giving an overall infec-
tion rate of 4.6% (95% CI 4.0 to 5.2) (Table 2). Only one
study had a superficial infection rate above 10% (Table 1).
The incidence for superficial infection was 1 per 561 days
of treatment or 1.8 per 1000 catheter treatment days.
We identified catheter-related infections of any descrip-
tion in 257 patients in the same nine studies (Table 1) giv-
ing an overall infection rate of 6.1% (95% CI 5.4 to 6.8)
(Table 2). Overall infection rates were above 10% in two
studies (Table 1). The incidence for any catheter-related
infection was 1 per 425 days of treatment or 2.4 per 1000
catheter treatment days. Numbers and percentages for
deep and superficial infections do not equal any catheter-
related infection because of different numerators and
denominators from different studies. We did not include
three studies reporting only deep infections in the any
catheter-related infection column (Table 1), since these
were a small proportion of the total infections. In addi-
tion, one study [20] reported five patients with general-
ised symptoms of infection who did not have local
infection. These 11 patients help explain the difference in
numbers between deep plus local infections (57+211 =
268) and any catheter-related infections (257).
Sensitivity analyses
Three studies [1,19,20] reported principally or wholly on
non-cancer or perioperative patients. The average catheter
duration in two of them was 9.3 days, and in the third the
Flow chart of studies Figure 1
Flow chart of studies.B
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Table 1: Detailed results from individual studies
Deep infection Superficial infection Any catheter-related infection
Study Patients Cohort Number of 
patients
Catheter 
duration 
(days)
Number 
with 
infection
Percent of 
patients 
affected
Per 1000 
catheter 
days
Number 
with 
infection
Percent of 
patients 
affected
Per 1000 
catheter 
days
Number 
with 
infection
Percent of 
patients 
affected
Per 1000 
catheter 
days
Aldrete 1998 Noncancer Retrospective 504 2 to 80 days 4 0.8 no data 5 1.0 no data 9 1.8 no data
Cherry 1985 Cancer Prospective 50 4200 0 0.0 0.0 2 4.0 0.5 2 4.0 0.5
Crawford 1983 Cancer (94) and benign (11) pain Retrospective 105 6825 1 1.0 0.1 no data no data
Crul 1991 Cancer Retrospective 110 8650 0 0.0 no data 5 4.5 no data 5 4.5 no data
de Jong 1994 Cancer Retrospective 149 6969 3 2.0 0.4 no data no data
Du Pen 1990 Cancer (339) and AIDS (11) Retrospective 350 32354 23 6.6 0.7 30 8.6 0.9 53 15.1 1.6
Erdeine 1991 Cancer Prospective 225 10642 0 0.0 0.0 9 4.0 0.8 9 4.0 0.8
Holt 1995 Mixed Prospective 1000 11901 11 1.1 0.9 53 3.6 3.0 59 5.9 5.0
Maier 1994 Perioperative Retrospective 1621 12540 0 0.0 0.0 46 2.8 3.7 46 2.8 3.7
Plummer 1991 Cancer Retrospective 284 27264 1 0.4 0.0 22 7.7 0.8 23 8.1 0.8
Smitt 1998 Cancer Retrospective 91 4326 12 13.2 2.8 39 42.9 9.0 51 56.0 11.8
Zenz 1985 Cancer Prospective 139 9716 2 1.4 0.2 no data no data
Patients in studies reporting the outcome 4628 4235 4235
Overall result 4628 135387 57 1.23 0.42 211 4.58 1.78 257 6.07 2.35BMC Palliative Care 2007, 6:3 http://www.biomedcentral.com/1472-684X/6/3
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duration was between two and 80 days [12]. These three
studies were also the largest studies, with more than 500
patients each (3,125 patients, 68% of the total; 25,000
catheter days, 19% of the total). The other nine studies
were smaller, with between 50 and 350 patients each
(1,503 patients, 22% of the total; 111,000 catheter days
81% of the total), and reported predominantly on cancer
patients with average catheter duration of 74 days. Sensi-
tivity analysis compared the three larger studies of shorter
catheter duration in patients without cancer with the nine
smaller studies of longer catheter duration in patients
with cancer, and prospective and retrospective studies
within the nine cancer studies (Table 3).
For deep, superficial, or overall infection, the smaller stud-
ies with long catheter duration in cancer had higher infec-
tion rates, some three or four times higher than the larger
studies with a shorter catheter duration in mainly non-
cancer patients. For instance, the deep infection rate in the
larger, shorter, studies was 0.48%, while in the longer
studies in cancer it was 2.8%; one cancer patient in 35
with a long duration epidural catheter would have a deep
infection. The incidence per 1000 catheter days for super-
ficial and deep infection in these smaller studies was a half
to a third that in larger studies (Table 3). In the longer,
cancer, studies the small number of events in the three
prospective studies (one of which [15] had information
only on deep infection) meant that no reliable estimate of
effects of study design could be made (Table 3).
Outcome with deep infection
Outcomes of infections were reported in six studies
[2,11,12,15,16,18]. One of them [18] reported that one of
three patients with a deep infection died. Another [2]
reported that three of twelve with deep infections died,
while the remaining nine had a good outcome. The other
four studies reported the outcome of patients with super-
ficial and/or deep infections as good. Overall, four of 57
patients (7%; 1 in 14 patients) with deep infections died,
although we cannot be certain that the cause of death was
solely due to the epidural infection. Good outcomes
occurred in 41 of 57 patients (72%), and the outcome in
12 patients (21%) was not reported.
If the risk estimate of deep epidural infection in cancer
patients with long duration catheters is 1 in 35 patients,
and the risk of death from deep epidural infection is 1 in
14, then an overall risk of death from deep epidural infec-
tion in cancer patients with long duration catheters is of
the order of 1 in 500.
Table 3: Sensitivity analysis
Larger studies 
Postoperative, 
noncancer
Smaller studies 
Predominantly 
cancer
Prospective cancer 
studies
Retrospective 
cancer studies
Infection Outcome patients Result patients Result patients Result patients Result
Deep infection Percent of patients 15/3125 0.48 42/1503 2.8 2/414 0.48 39/979 4.0
Incidence per 1000 days 0.45 0.41 0.08 0.50
Superficial infection Percent of patients 87/3125 2.8 107/1110 9.6 11/275 4.0 61/725 8.4
Incidence per 1000 days 3.4 1.3 0.74 0.95
Overall infection Percent of patients 114/3125 3.6 143/1110 13 11/275 4.0 74/725 10
Incidence per 1000 days 4.3 1.8 0.74 1.2
Table 2: Main results for deep, superficial and any infection
Site of infection
Deep Superficial Any catheter-related
Number of studies 12 9 9
Number of patients with infections 57 194 257
Total number of patients 4628 4235 4235
Percentage of patients with infection 1.2 4.6 6.1
Risk of infection per 1000 catheter days 0.4 1.8 2.4
Mean days of catheter use before one infection occurs 2391 561 425
Note that the infection rate for deep plus superficial numbers and percentages does not necessarily equal that for any catheter-related infection 
because of different numerators and denominatorsBMC Palliative Care 2007, 6:3 http://www.biomedcentral.com/1472-684X/6/3
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Discussion
A recent systematic review of efficacy of epidural, sub-
arachnoid, and intracerebroventricular opioids for cancer
pain [21] had information on 2,402 patients in 72 uncon-
trolled studies reporting on efficacy. It found eight spinal
infections, without detailed description, in 154 patients
(5.2%). By contrast, the present systematic review concen-
trated on reports of epidural infection, and found 57 cases
of deep epidural infection in 4,628 patients (1.2%) in 12
uncontrolled studies. In comparing these two approaches,
only one study (published as an abstract) included in the
Ballantyne & Carwood review [21] was missed by our
approach, and that reported only a single superficial infec-
tion in 129 patients. Several studies included in this
review may have been eligible for that of Ballantyne &
Carwood. Using adverse event information found solely
in studies of efficacy appears to have restricted the amount
of information available on serious adverse events.
Information was available for adverse events associated
with the use of epidural catheters in 1.4 million women
during childbirth [4] and the short duration of catheter
use during childbirth minimised the likelihood of deep
infection, occurring in 1 in 145,000 women (7 per mil-
lion). In 14,105 patients undergoing cardiothoracic or
vascular surgery with epidural catheters, no deep epidural
infections were noted [22]. Results from situations where
epidural catheters are used for only a few days are unlikely
to be representative for those where catheter use is for
months.
When catheters were in place for more than seven days in
this chronic setting, deep infection occurred in 1 in 83
patients, 1,800 times more frequently than in obstetrics.
This may be related to catheter duration, because sensitiv-
ity analysis (Table 3) demonstrated that studies of cathe-
ter use of shorter catheter duration (generally less than 10
days) had a deep infection rate of 0.48%, but when aver-
age catheter duration was 74 days the deep infection rate
was 2.8%. While a strong link between catheter duration
and deep infection rate may be inferred, differing case mix
may also be relevant. The higher rate was in predomi-
nantly cancer patients, who are usually older and with
clinical problems that might make infection more likely,
though it was interesting (Table 3) that deep infection
rates per 1,000 patient days in cancer patients were much
the same as in mainly preoperative patients.
The best estimate we have, then, is that 1 in 35 cancer
patients with long duration epidural catheters will have a
deep epidural infection, and that about 1 in 500 may die
of infection-related causes. The small number of cases and
deaths, lack of information on cause of death, and issues
like use of prophylactic antibiotics or predisposing clini-
cal factors make this a most uncertain estimate.
The fact that the percentage of patients with deep epidural
infection increased with catheter duration while the inci-
dence per 1000 catheter days fell is not inconsistent. The
reason is that longer duration catheters contribute more
to the number of catheter days. Studies of short catheter
duration had an average of about 10 days per patient or
less, while those of longer duration had catheter duration
per patient more than seven times longer. There would
have to be seven times more patients with an infection for
the incidence per 1000 patient days to be the same, but
deep epidural infections actually increased only five-fold.
In addition, the original studies are generally silent on
issues like use of prophylactic antibiotics, which might
contribute to some patients having long catheter place-
ment without infection.
While epidural infection is undoubtedly a serious event,
the outcomes are not always disastrous. Nussbaum et al
[3] reported that 26 of 40 patients (65%) with an epidural
abscess had a good, 9 (23%) a fairly good, and 5 (12%) a
bad outcome. This is similar to outcomes after deep epi-
dural infection in this review, with a good outcome in
72% and a bad outcome in 7%. A recent prospective study
[23] concerning meningitis outcome after paravertebral
Deep infection rates in individual studies (size of symbol pro- portional to number of patients; inset scale) Figure 2
Deep infection rates in individual studies (size of symbol pro-
portional to number of patients; inset scale).
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injections in eight patients showed a favorable outcome
in three, handicap in three, and death in one.
There are several weaknesses in this review, not least the
relatively small number (57) of deep epidural infections,
increasing the possible effects of chance [24]. It was not
possible to identify concomitant risk factors that might
suggest which patient is most at risk, how infections in
these patients might be prevented, rates of progression
from superficial to deep infection, or possible advantages
of using tunneled catheters. Because cultural, legal, or per-
sonal considerations may affect reporting, serious adverse
events may also be under-reported. Limited numbers of
events also meant that no reliable estimate of the impact
of prospective and retrospective design could be made,
and information comes predominantly from retrospective
studies.
A further limitation is that a variety of epidural systems
(percutaneous, ports, tunnelled silastic and tunnelled
polyamide) could have been used. It may be that they
were associated with different infection rates, but with the
small numbers of actual infections, it would have not
been possible to come to any reliable conclusions with the
data available.
Finally, searching for observational studies is more diffi-
cult than for randomised trials, despite considerable
efforts using electronic databases. Electronic searching of
a single database yielded only 60 to 80% of relevant
observational studies [25]. Hand searching journals, and
checking of reference lists of retrieved papers increases
retrieval of relevant papers. We looked for studies in elec-
tronic databases, handsearched five main anaesthesia
journals, and checked the reference lists of all included
studies, and many excluded studies and reviews. Most (9/
12) of the studies identified for this review were found in
reference lists of previously retrieved articles and reviews,
and 270 papers had to be read and their reference lists
examined to ensure as complete a survey as possible. Only
three relevant studies were found in electronic searches.
Particular care should be taken to avoid catheter implan-
tation when there is either local (skin infection at punc-
ture site) or systemic signs of infection. Ongoing steroid
therapy may also predispose to epidural infection. When
catheter placement is likely to be prolonged, special care
needs to be given to catheter hygiene.
The results of this systematic review provide the best, if
limited, available estimate for epidural infections in
patients with long-term epidural catheters for analgesia.
Larger numbers for both numerator and denominator
would improve the strength of the estimate, and larger
prospective consecutive series would be welcomed.
Conclusion
The best estimate is that one person in 35 with an epidural
catheter in place for 74 days for relief of cancer pain can
be expected to have a deep epidural infection, and that
about 1 in 500 may die of infection-related causes.
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